Sensorimotor gating measured by prepulse inhibition (PPI) of the acoustic startle response (ASR) has been proposed as one of the most promising electrophysiological endophenotypes of schizophrenia. During the past decade, a number of publications have reported significant associations between genetic polymorphisms and PPI in samples of schizophrenia patients and healthy volunteers.
Introduction
Prepulse inhibition (PPI) of the acoustic startle response (ASR) is defined as a substantial reduction of the startle amplitude that occurs when a startling stimulus is preceded within a timeframe of 20-500 ms by a stimulus of lower intensity than the startling stimulus (Graham, 1975) . PPI has been shown to occur across species ranging from mollusks and fishes to mammals including non-human and human primates (Burgess and Granato, 2007; Frost et al., 2003; Hoffman and Searle, 1965; Ison and Leonhard, 1970; Krauter et al., 1973; Linn and Javitt, 2001) . Animal studies carried out predominantly in rodents suggested that PPI is regulated by a cortico-striato-pallido-pontine (CSPP) circuitry including frontal and mediotemporal regions, ventral striatum, ventral pallidum, and pontine regions of the brainstem (Fendt et al., 2001; Swerdlow et al., 2001) . Within the CSPP circuit, several neurotransmitters have been demonstrated to play a major role in the mediation of PPI such as dopamine, noradrenaline, serotonin, acetylcholine, glutamate, and γ-aminobutyric acid (GABA) Koch, 1999) . Consequently, PPI has been proposed as a "window" into brain chemistry potentially allowing the identification of neuropharmacological alterations in specific psychiatric disorders with PPI abnormalities (Braff, 2010) . In fact, lower PPI levels have been reported for several neuropsychiatric disorders Kohl et al., 2013; Quednow, 2008) , but were replicated best for schizophrenia spectrum disorders (e.g., Braff et al., 1992; Cadenhead et al., 1993; Kumari et al., 2000; Ludewig et al., 2003; Parwani et al., 2000; Quednow et al., 2006; Swerdlow et al., 2014) . Given that PPI shows such a robust association with schizophrenia and because it is heritable (Anokhin et al., 2003; Greenwood et al., 2007; Willott et al., 1994; , reduced in unaffected relatives of schizophrenia patients (Cadenhead et al., 2000; Kumari et al., 2005) , and already decreased in early (prodromal) stages of the disease (Quednow et al., 2008a; Ziermans et al., 2011; , PPI was suggested as an promising candidate of an intermediate or endophenotypic marker in genetic studies of schizophrenia (Braff and Light, 2005; Gottesman and Gould, 2003) .
Specifically, the substantial heritability of PPI in humans -ranging from 29% to 50% across a number studies -suggests PPI as a favorable target for genetic analyses (Anokhin et al., 2003; Greenwood et al., 2007; Hasenkamp et al., 2010; Seidman et al., 2015) . Additionally, it was recently shown that PPI revealed substantially increased heritability (47%) in 97 families multiply affected by schizophrenia when compared with a 96 families, in which only a single individual was affected (2%). This finding further promotes the assumption that a commonality of genes underlies both schizophrenia and PPI (Greenwood et al., 2016) .
The endophenotype concept assumes that an endophenotypic marker is a heritable, quantifiable, and stable trait, which is determined by a smaller number of genes compared to the respective complex disease phenotype . Accordingly, in the last decade several research groups aimed to identify gene effects on the expression of PPI. The first positive findings were published in 2008, where associations of PPI with single nucleotide polymorphisms (SNPs) of the neuregulin-1 (NRG1, rs3924999) (Hong et al., 2008) , catechol-O-methyltransferase (COMT, rs4680) (Roussos et al., 2008b) , dopamine D3 receptor (DRD3, rs6280) (Roussos et al., 2008a) , and the serotonin-2A receptor (5-HT2AR, rs6311/6313) gene (Quednow et al., 2008b) have been reported from hypothesis-driven single association studies. Since then a number of further single association studies reported significant associations of PPI with numerous SNPs, which mainly have been identified as schizophrenia risk genes previously (for a list of studies and SNPs see Table 1 and 2, respectively).
The only SNPs that have been replicated in at least two independent samples so far are CHRNA3 (rs1051730) (Petrovsky et al., 2010) , 5-HT2AR (rs6311/6313) (Quednow et al., 2008b; , COMT (rs4680) Quednow et al., 2009; 2010; Roussos et al., 2008b) , NRG1 (rs3924999) (Hong et al., 2008) , TCF4 (rs9960767) (Quednow et al., 2011) , and DRD2 (rs1800497) (Volter et al., 2012) . However, for most of these SNPs also negative findings have been reported. Most recently, the first explorative genome-wide association study (GWAS) identified two non-coding loci (rs61810702 and rs4718984) that were co-localized with expression quantitative trait loci related with the gene expression of nerve growth factor (NGF) and calneuron 1 (CALN1) genes. Additionally, a higher polygenic risk score for schizophrenia was associated with lower PPI (Roussos et al., 2016) .
The heterogeneity of these genetic results implies i) that there are probably no single genes with a high impact on PPI and ii) that there are likely also some false positive results considering thatfrom today's perspective -many of the previous studies are strongly underpowered and lack replication samples (Button et al., 2013) . One way to reduce the number of false positive (but also false negative) results in psychiatric genetics is the application of a meta-analysis, in which all available data are included (Levinson, 2005; Lohmueller et al., 2003) . Therefore, we performed a systematic meta-analysis of all genotype-SNP associations published so far using a weighted Zmethod approach (Stouffer et al., 1949) . We additionally included three independent data sets coming from samples that have been published before for reporting of genotype-PPI associations but for which also yet unpublished genotype or GWAS data existed (Petrovsky et al., 2010; Quednow et al., 2008b; 2010; Roussos et al., 2016) . Genetic variants were included into the analysis if they were available in at least two independent samples. In order to control for multiple comparisons, a false discovery rate (FDR) method based on estimation of tail area-based FDR was applied (Strimmer, 2008) . The aim of this systematic meta-analysis was the identification of the most robust i.e., significant genotype-PPI associations.
Methods

Eligibility criteria
Human association studies (single associations and GWAS) with genetic variants reporting pvalues and direction of effect for PPI-genotype associations in samples of healthy controls or patients with schizophrenia spectrum disorders. To be included, a gene variant must have been available in at least two independent samples.
Information sources and search strategy
With the search term (("prepulse inhibition" OR "sensorimotor gating") AND (mutation OR Table 1) . After checking, if at least two p-values of a specific genotype-PPI and from independent samples are available (e.g., in two publications or in a publication and an unpublished data set), 120 single observations from 16 independent samples with 2,660 study participants and 43 polymorphisms were included in the meta-analysis ( Table 2) .
Inclusion of unpublished data
The authors included unpublished genotype-PPI association data from three samples that have been published before: (1) the LOGOS sample recruited in Crete, Greece, consisting of healthy volunteers (max. n=686) (Roussos et al., 2016) , (2) a sample of healthy volunteers (max. n=100) from London, UK (Petrovsky et al., 2010; Quednow et al., 2009; , and (3) a sample of patients with schizophrenia spectrum disorders (max. n=107) from Bonn, Germany (Petrovsky et al., 2010; Quednow et al., 2008b; 2010; . P-values of yet unpublished genotype-PPI associations have been calculated using the same statistical approach as previously reported, e.g., using the same covariates such as sex, smoking status, and antipsychotic medication (London and Bonn samples: Quednow et al., 2011) . The final studies, cohorts and number of samples per study included in the meta-analysis is shown in Table 1 and 2.
Statistical Analysis
We sum the association evidence across studies using a weighted Z-method approach where every study is weighted by the effective sample size (Stouffer et al., 1949) . Briefly, in each study, we convert P i P-values into Z i signed Z-scores based on the Δ i direction of effect using the following equation: * ∆ .
We then estimate overall Z score by summing Z-scores for each genetic polymorphism using weights proportional to the square-root of the sample size for each study:
where and N i is the sample size of study i. Finally, the overall Z score is converted back to overall P-value for a given genotype based on:
For multiple testing correction, we applied FDR at combined P-values estimated based on fdrTool in R (Strimmer, 2008) . The Cohen's d effect sizes for the strengths of association were estimated from Z-values according to Rosenthal (1984) . For estimation of effect sizes in schizophrenia GWAS study we used the average odds ratio of 1.1 across all genome-wide significant SNPs and estimated Cohen's d based on:
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As sex effects are well-documented for the rs4680 COMT SNP (Tunbridge and Harrison, 2011) , and as strong sex differences in rs4680 COMT effects on PPI were recently reported in a non-trivial sample of healthy subjects (Swerdlow et al., 2017) , we additionally analyzed sex effects for this SNP only. Based on the existing studies, we are well powered to study the COMT association in males only as the majority of the included samples with known gender (92% or 870 out of 943) were males.
Results
In this study, we examined the associations of SNPs and PPI of ASR. We evaluated a total of 43 SNP-PPI associations, while for each SNP two to six samples were available (mean 2.8, standard deviation 1.1, median 2.0 samples). Statistical significance was defined as an FDR-adjusted p-value of 0.05 or smaller. At this threshold, four index SNPs were significant. The strongest association was between COMT rs4680 and PPI (P = 5.5*10 -5 , FDR = 0.002, Cohen's d = 0.28) in male samples only ( Table 2 ). The other three loci with significant association with PPI were: GRIK3 rs1027599 ( and PRODH rs385440 (P = 0.006, FDR = 0.050, Cohen's d = 0.27). As expected, the detected Cohen's d effect sizes are small according to the definition of Cohen (1988) and none of these associations survived a genome-wide correction (P < 5*10 -8 ). Notably, we also found a significant effect for COMT rs4680 in both males and females, but with smaller effect size that did not survive multiple testing corrections (P = 0.01, FDR = 0.057, Cohen's d = 0.15), indicating a putative genderspecific effect of COMT on PPI.
Discussion
The aim of this meta-analysis was the identification of robust associations between gene polymorphisms and PPI of the ASR. Given that PPI was repeatedly proposed as an endophenotype of schizophrenia , this investigation might elucidate which genes may robustly contribute to the low PPI levels of schizophrenia patients and presumably to the disease itself. We thus analyzed published and unpublished data resulting in the inclusion of 120 single observations from 16 independent samples with 2,660 study participants and 43 polymorphisms. After multiple testing corrections based on an FDR approach, four polymorphisms were significantly associated with PPI. In males, the COMT rs4680 (Val158Met) significant association with PPI. Regarding GRIK3 rs1027599, the T allele carriers showed lower PPI, while the same was true for TCF4 rs9960767 C and PRODH rs385440 A allele carriers. In fact, when the widely accepted threshold for genome-wide multiple corrections (P < 5*10 -8 ) is applied, none of the results is powerful enough to survive. However, it has to be taken into account that the power of this meta-analysis (sample size range: N=436 to 1224) was much lower, e.g., compared to previously published mega-analyses in schizophrenia genetics, including ten thousands of participants (Ripke et al., 2013; Steinberg et al., 2011) . Nevertheless, the effect sizes of the significant SNPs in the present meta-analysis are small (Cohen's d = 0.19 to 0.28) in the sense of Cohen's definition (Cohen, 1988) but relatively strong considering the strengths of genetic associations commonly shown in metaanalysis of GWAS in schizophrenia (Cohen's d = 0.05 based on Schizophrenia Working Group of the Psychiatric Genomics, 2014).
The COMT gene effect on PPI is highly plausible as the COMT enzyme is involved in in the metabolic inactivation of dopamine and norepinephrine in regions with a low density of dopamine and noradrenaline transporters specifically in the frontal cortex (Rivett et al., 1982) . The rs4680 polymorphism leads to an amino acid substitution of methionine for valine changing the metabolic rate of the enzyme. Consequently, compared to methionine homozygotes, valine homozygotes have a 3 to 4-fold stronger COMT enzyme activity and, thus, an increased catabolism of catecholamines in the frontal cortex (Lachman et al., 1996) . Animal and human studies suggest that PPI is critically modulated by dopamine and noradrenaline neurotransmission at several stages of the CSPP circuit Swerdlow et al., 2001) . Moreover, COMT messenger RNA is highly expressed in the prefrontal cortex and the hippocampus and less in the striatum, the ventral tegmental area, or the substantia nigra (Tunbridge et al., 2006) . Considering that these structures are participating in the CSPP circuit, it is likely that the COMT polymorphism influences PPI at the prefrontal or hippocampal level Quednow et al, 2010) . Specifically, lower prefrontal dopamine concentrations probably contribute to reduced PPI levels in valine allele carriers as is was shown that reduced dopamine activity in the prefrontal cortex goes along with a disruption of PPI (Bubser and Koch, 1994; Ellenbroek et al., 1996; Zavitsanou et al., 1999) . In addition, drug-induced inhibition of the COMT enzyme with tolcapone leads to PPI enhancement only in the COMT Val carriers Giakoumaki et al., 2008; Roussos et al., 2009b) . In line with these human data, it was shown that the effects of COMT inhibition by tolcapone on amphetamine-modified PPI were categorically different in rat strains exhibiting low vs. high levels Comt expression in the forebrain (Swerdlow et al., 2013) . Moreover, genetic associations between COMT and psychiatric phenotypes frequently display sex differences (Tunbridge and Harrison, 2011) . Accordingly, COMT rs4680 genotype effects on PPI have been demonstrated particularly in males, while the gene effects were absent, less strong, or even reversed in females (Montag et al., 2008; Quednow et al., 2009; 2010; Roussos et al., 2008b; Swerdlow et al., 2017) . Finally, COMT rs4680 has been proposed to be a risk gene for schizophrenia for a long time but recent meta-analytical results are conflicting (GonzalezCastro et al., 2016; Taylor, 2017) . Again, associations between COMT rs4680 and schizophrenia or schizotypy have been demonstrated primarily in males but not females (for reviews see Tunbridge and Harrison, 2011) . Thus, the sex-specific effect of the COMT rs4680 on PPI shown here is in agreement with a variety of previous findings. was reported for a girl with developmental delay (Takenouchi et al., 2014) . Interestingly, in a recent twin study, a GRIK3 gene set was associated with overall startle responses (Vaidyanathan et al., 2014) , raising the question if the association with PPI shown here is rather an epiphenomenon of changes in startle reactivity (Csomor et al., 2008) . Moreover, the kainate antagonist LY382884 reduced both exaggerated ASR and PPI deficits observed in mice with genetically reduced NMDA receptor expression (Duncan et al., 2010) . However, these results might be explained by the changes in ASR again, as strongly elevated startle responses can result in low PPI levels also in mice (Csomor et al., 2008) .
TCF4 belongs to the superfamily of basic Helix-Loop-Helix (bHLH) transcription factors that can act as a transcriptional repressor or activator in a context specific fashion. It can be considered as an integrator ('hub') of several bHLH networks controlling critical steps of various developmental and plasticity related transcriptional programs in neurons (Quednow et al., 2014) . Haploinsufficiency of the TCF4 gene causes the Pitt-Hopkins syndrome -a severe neurodevelopmental disease characterized by mental retardation, microcephaly, epilepsy, facial dysmorphisms, and intermittent hyperventilation -, suggesting that TCF4 is critical for the development of the mammalian nervous system (de Pontual et al., 2009; Zweier et al., 2007) . Three large but also partially overlapping meta-analyses of GWAS consistently identified that common TCF4 polymorphisms are associated with the risk of schizophrenia (Schizophrenia Psychiatric Genome-Wide Association Study, 2011; Stefansson et al., 2009; Steinberg et al., 2011) . In these analyses, two SNPs at the intron located between the internal exon 4 and internal exon 5 of human TCF4 gene on chromosome 18q21. 2 (rs9960767, rs17512836) and an intragenic SNP near the TCF4 gene (rs4309482) (Aberg et al., 2013) . These results have contributed to the view that TCF4 SNPs belong to the best-replicated schizophrenia susceptibility genes. A potential disturbance of TCF4 function in schizophrenia would be in line with the assumption that schizophrenia is a neurodevelopmental disorder (Quednow et al., 2014) ; however, the exact functional impact of the discussed TCF4 SNPs has still to be elucidated. Finally, transgenic mice moderately overexpressing TCf4 in the brain as well as TCf4 haploinsufficient mice both display profound reductions in PPI (Brzozka et al., 2010; Kennedy et al., 2016) . Beyond PPI, TCF4 SNPS including rs9960767 have been shown to be associated with another proposed endophenotype of schizophrenia:
P50 suppression also called "sensory gating"; however, this association was only present in smoking individuals but not in never-smokers . Taken together, the significant association of TCF4 rs9960767 and PPI in human cohorts reported here is neurobiologically and pathophysiologically plausible as well.
PRODH encodes the enzyme proline oxidase, which is involved, among other functions, in the conversion of proline to D-1-pyrroline-5-carboxylate (P5C) in mitochondria. P5C is subsequently converted to glutamate or GABA, two neurotransmitters critically implicated in the pathophysiology of schizophrenia (Roussos et al., 2009a) . Together with COMT, PRODH is located at 22q11 and, thus, both genes belong to the ~30 genes affected by the 22q11 deletion syndrome (Velo-Cardio-Facial or DiGeorge syndrome). Individuals with a 22q11 deletion syndrome show a strongly elevated risk for schizophrenia symptoms (Prasad et al., 2008) as well as reductions of PPI (Sobin et al., 2005a, b) . In addition, rodent models of the 22q11 syndrome are associated with deficits in PPI (Diamantopoulou et al., 2017; Didriksen et al., 2017; Gogos et al., 1999) . Previous studies suggested a possible role of the PRODH gene variations, in the pathogenesis of schizophrenia. Specifically, PRODH haplotypes consisting of rs372055 (1945T>C), rs450046 (1766A>G), and rs385440 (1852G>A) SNPs were significantly associated with schizophrenia, indicating that the alleles 1945C, 1766G, and 1852A are overtransmitted in schizophrenia patients (Li et al., 2004; Liu et al., 2002) . The haplotypes, which included rs385440, is associated with PRODH hyperactivity potentially resulting in reduced proline levels and increased P5C/Glu availability in the central nervous system (Phang et al., 2008) and these changes might induce changes in the modulation of PPI (Roussos et al., 2009a) . As both COMT and PRODH SNPs seem to have an impact on PPI and given that these genes are within 22q11 locus, further studies should investigate gene-gene interactions of both variants with regard to PPI.
Limitations of our meta-analysis include the small number of included studies and sample sizes making the estimates of effect sizes less reliable. Moreover, for most of the SNPs only two independent samples were available. It should be noticed, that the PRODH effect on PPI was indeed similarly strong as the COMT effect in males but that the PRODH sample size was nevertheless the lowest amongst all analyzed SNPs. Thus, the PRODH effect is likely less reliable than the COMT effect. Moreover, similar as for PRODH, the GRIK effect was calculated from only two studies, while three studies were included for TCF4 and four regarding COMT (in males, and six for COMT including females). Consequently, the GRIK effects might also be less robust compared to TCF4 and COMT (in males). Finally, we used a weighted Z-method approach using reported p-values to calculate the meta-analysis and consequently, statistical differences between studies (e.g., regarding the inclusion of different sets of covariates) have not been considered. Accordingly, as we did not use the original data sets of previously published work we were not able to adjust the results for the common confounding factors affecting PPI, such as gender and menstrual cycle, smoking, startle magnitude, as well as medication (Quednow, 2008) . Particularly in patient samples, PPI-gene associations could have been masked by the potential PPI-enhancing impact of antipsychotic medication (Quednow et al., 2006; . However, several previous studies have controlled for such confounding factors and reported adjusted p-values, but not all. The additional analyses of so far unpublished data from patients with schizophrenia spectrum disorders reported in the present paper in fact considered smoking, sex, and antipsychotic medication status as covariates and only the adjusted p-values were used for the meta-analysis. Nevertheless, the overall strength of the gene effects might have been biased by confounding factors such as antipsychotic medication. Another limitation is that the included studies employed a variety of different PPI setups. Given that it has not been investigated systematically yet, which PPI parameters (e.g., prepulse and pulse intensities, stimulus-onset asynchrony, number of stimuli, intertrial intervals) might provide an optimal signal-to-noise ratio with regard to gene effects (or if genes might specifically influence PPI at various conditions), it remains unclear how the heterogeneity of PPI setups used in the included studies might have affected our results.
Beyond PPI, several further electrophysiological "gating" or filtering" paradigms have been proposed as potential endophenotypes and clinical biomarkers of schizophrenia, such as P50 suppression, P300 and P3a, and mismatch negativity (MMN) . Many studies have investigated the associations between polymorphisms and these electroencephalographic measures but no meta-analysis has been performed for any of these markers yet (Owens et al., 2016) .
Specifically, the MMN and the P3a event related potential component might be highly promising targets for future endophenotype-related genetic meta-analyses given that both are strongly, robustly, and stably affected in schizophrenia patients and both show considerable heritability .
Taken together, the present meta-analysis revealed that four SNPs located on genes that have been associated with schizophrenia previously, are robustly correlated with the expression of PPI in humans as well. These associations are neurobiologically plausible as the respective gene products have been shown to be involved in the CSPP circuit processing PPI Koch, 1999; Swerdlow et al., 2001) . Although the effect sizes of the gene effects on PPI are relatively strong (at least when compared to the extremely weak gene effects shown in meta-analysis of GWAS in schizophrenia) none of the results would have survived a strict genome-wide correction of the alphalevel. This indicates that PPI -like schizophrenia itself -is highly polygenic. Thus, the question that still has to be answered in the future is whether the hitherto proposed schizophrenia endophenotypes are in fact less polygenic as the complex disease phenotype, so that endophenotypes can be used to predict the risk for schizophrenia or if they can be used to discover new neurobiological treatment targets. 
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